Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease (Q24246591)

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

Seretide for obstructive lung disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB2

7 January 2021

10.1002/14651858.CD003794.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2666683

2666683

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference